selenow Antibody

What is SELENOW and what are its key biological functions?

SELENOW (Selenoprotein W) is a small cytoplasmic protein with 87 amino acid residues and a molecular mass of approximately 9.4 kDa in humans. It belongs to the SelWTH protein family and is widely expressed across numerous tissue types. The primary function of SELENOW is as a glutathione (GSH)-dependent antioxidant, suggesting its critical role in cellular redox homeostasis. Current research indicates it may be involved in redox-related processes and potentially plays a significant role in the myopathies associated with selenium deficiency .

Recent studies have expanded our understanding of SELENOW's biological significance, demonstrating its importance in inflammatory resolution in experimental colitis models through regulation of the Epidermal Growth Factor Receptor (EGFR) pathway . Additionally, gender-specific functions have been observed in brain tissue, particularly related to oligodendrogenesis during fear memory formation .

What are the essential characteristics of commercially available SELENOW antibodies?

Most commercial SELENOW antibodies are polyclonal antibodies raised in rabbits using recombinant human Selenoprotein W protein fragments as immunogens. For instance, several manufacturers produce antibodies targeting the amino acid region 11-86 of the human SELENOW protein . These antibodies typically demonstrate human reactivity, with some cross-reactivity to mouse and rat orthologs depending on the specific product and manufacturer.

Available formats include unconjugated antibodies as well as those conjugated with detection molecules like HRP, biotin, or FITC for specialized applications . When selecting a SELENOW antibody, researchers should consider the specific application requirements, including the target species, detection method, and experimental conditions. Most high-quality SELENOW antibodies have undergone protein G purification with >95% purity and have been validated for applications such as ELISA, immunohistochemistry (IHC), and Western blotting .

What applications are SELENOW antibodies most commonly used for in research?

SELENOW antibodies are employed in various research applications, with the most common being:

• Western Blotting: Used to detect and quantify SELENOW protein expression levels in cell or tissue lysates. Typical dilutions range from 1:500 to 1:1000, though this can vary by manufacturer .

• Immunohistochemistry (IHC): Applied to detect SELENOW in fixed tissue sections, helping to understand the tissue-specific localization of this protein. Recommended dilutions generally range from 1:20 to 1:200 .

• ELISA: Used for quantitative detection of SELENOW in solution-based samples .

• Immunofluorescence: Applied to visualize the subcellular localization of SELENOW in cultured cells or tissue sections .

These antibodies have proven particularly valuable in studies investigating oxidative stress responses, redox signaling pathways, and the pathophysiology of selenium deficiency. Recent applications include studying SELENOW's role in inflammatory regulation and brain function using knockout mouse models .

What are the optimal storage and handling conditions for SELENOW antibodies?

For maximum stability and longevity, SELENOW antibodies should be stored at -20°C or -80°C upon receipt . Most commercial preparations are supplied in a liquid format with storage buffers containing preservatives (such as 0.03% ProClin 300) and stabilizers (typically 50% glycerol in PBS at pH 7.4) .

To maintain antibody integrity:

• Avoid repeated freeze-thaw cycles, which can degrade antibody quality. Aliquot upon first thaw if multiple uses are planned.

• When working with the antibody, thaw on ice and return to storage promptly after use.

• Handle with appropriate precautions, particularly for antibodies containing preservatives like ProClin, which manufacturers identify as potentially hazardous substances that should be handled by trained personnel .

• Before use, centrifuge briefly to collect the solution at the bottom of the vial, especially after shipping or transport.

• Diluted working solutions should be prepared fresh before each experiment for optimal results.

How can researchers optimize SELENOW antibody dilutions for different experimental techniques?

Optimizing antibody dilutions is crucial for achieving reliable and reproducible results while minimizing background signals and conserving valuable reagents. Based on published research protocols, the following methodological approaches are recommended:

For Western Blotting:

• Begin with a dilution range of 1:500 to 1:1000 for most SELENOW antibodies

• Perform a dilution series experiment (e.g., 1:250, 1:500, 1:1000, 1:2000) using positive control samples

• Evaluate both signal intensity and background for each dilution

• Include appropriate loading controls (e.g., β-Actin at 1:20,000) to normalize expression levels

• For chemiluminescence detection, ECL substrates with different sensitivities may require adjustment of antibody concentrations

For Immunohistochemistry:

• A wider dilution range is typically necessary, from 1:20 to 1:200

• Begin optimization with a median dilution (e.g., 1:100) on known positive control tissues

• Consider using an antibody titration matrix with different antigen retrieval methods

• Account for tissue-specific background by including negative controls lacking primary antibody

• Quantify signal-to-noise ratio to determine optimal working dilution

For Immunofluorescence:

• Higher concentrations may be needed compared to Western blotting, typically starting at 1:100 to 1:500

• Co-staining with cell-type specific markers can help validate specificity

• Always include controls to assess autofluorescence of the tissue/cells being studied

What methodological considerations are important when studying SELENOW in relation to EGFR signaling pathways?

Recent research has established connections between SELENOW and EGFR signaling pathways, particularly in colitis models . When investigating these relationships, several methodological considerations are essential:

• Co-immunoprecipitation approaches: When examining protein-protein interactions between SELENOW and EGFR pathway components, researchers should:

  • Use mild lysis buffers to preserve protein complexes

  • Include appropriate negative controls (IgG or isotype controls)

  • Confirm interactions through reverse co-IP experiments

  • Consider crosslinking approaches for transient interactions

• Phosphorylation state analysis: As EGFR signaling involves phosphorylation cascades, researchers should:

  • Use phospho-specific antibodies (e.g., pEGFR Y1068) alongside total EGFR antibodies

  • Include phosphatase inhibitors in all extraction buffers

  • Consider using Phos-tag™ gels for enhanced separation of phosphorylated proteins

  • Apply quantitative analysis to determine phosphorylation ratios

• Knockout model considerations: When using SELENOW knockout models to study EGFR signaling:

  • Compare age-matched and gender-matched controls due to observed gender-specific effects

  • Characterize baseline EGFR expression and activation in knockout versus wild-type models

  • Consider conditional knockouts if developmental effects complicate interpretation

  • Apply genome-wide approaches (e.g., proteomics) to identify compensatory mechanisms

• Stimulus-response experiments: To dissect functional relationships:

  • Design time-course experiments following EGF stimulation

  • Compare EGFR internalization and recycling rates in presence/absence of SELENOW

  • Consider using small molecule inhibitors of EGFR to determine pathway specificity

What are the best practices for validating SELENOW antibody specificity in experimental systems?

Validating antibody specificity is crucial for generating reliable research data. For SELENOW antibodies, researchers should implement the following validation approach:

• Genetic validation:

  • Test antibodies on samples from SELENOW knockout models - the complete absence of signal provides strong validation of specificity

  • Use siRNA or shRNA knockdown approaches as alternatives when knockout models are unavailable

  • Compare expression patterns across multiple tissue types with known SELENOW expression profiles

• Peptide competition assays:

  • Pre-incubate the antibody with excess recombinant SELENOW protein (such as the immunogen used to generate the antibody) before application

  • A significant reduction in signal indicates specificity for the target epitope

• Multiple antibody validation:

  • Compare results using antibodies from different suppliers or those targeting different epitopes

  • Concordant results strengthen confidence in specificity

• Western blot analysis:

  • Verify that the detected protein has the expected molecular weight (approximately 9.4 kDa for human SELENOW)

  • Examine expression patterns across multiple tissues with known SELENOW distribution

• Mass spectrometry confirmation:

  • For definitive validation, immunoprecipitate SELENOW and confirm identity with mass spectrometry

  • This approach can also identify potential interacting partners

How should researchers approach the quantitative analysis of SELENOW expression in comparative studies?

Accurate quantification of SELENOW expression is essential for comparative studies, particularly when examining disease states or experimental manipulations. The following methodological approaches are recommended:

• Western blot quantification:

  • Use appropriate loading controls (GAPDH, β-Actin, or β-Tubulin) for normalization

  • Apply densitometric analysis using software like ImageJ (version 1.53c or later)

  • Include a standard curve of recombinant SELENOW for absolute quantification

  • Average results from at least three biological replicates

  • Report both raw and normalized values

• Proteomics approaches:

  • TMT-based quantitative proteomics provides robust relative quantification across multiple samples

  • Ensure adequate sample size (n≥4 per group) for statistical power

  • Validate key findings with orthogonal methods like Western blotting

  • Consider absolute quantification using targeted proteomics approaches (AQUA, SRM/MRM)

• Immunohistochemical quantification:

  • Use digital pathology approaches with consistent imaging parameters

  • Develop standardized scoring systems based on staining intensity and distribution

  • Apply automated image analysis to reduce subjective interpretation

  • Include reference standards on each slide to account for batch effects

• Statistical considerations:

  • Apply appropriate statistical tests based on data distribution

  • Account for multiple testing when examining SELENOW across various tissues or conditions

  • Consider using ANCOVA when covariates may influence expression

  • Report effect sizes in addition to p-values

What technical challenges are commonly encountered when using SELENOW antibodies and how can they be addressed?

Researchers working with SELENOW antibodies may encounter several technical challenges. Here are the most common issues and recommended solutions:

• Low signal intensity:

  • Increase antibody concentration incrementally

  • Extend primary antibody incubation time (e.g., overnight at 4°C)

  • Use signal amplification systems (e.g., biotin-streptavidin)

  • Optimize antigen retrieval methods for fixed tissues

  • Consider using a more sensitive detection system

• High background or non-specific binding:

  • Increase blocking time and concentration (5% non-fat dried milk or BSA)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

  • Include additional washing steps with increased stringency

  • Pre-absorb antibody with tissues/cells lacking SELENOW expression

  • Use more specific secondary antibodies with minimal cross-reactivity

• Inconsistent results between experiments:

  • Standardize all protocol parameters (antibody lot, incubation times, temperature)

  • Prepare and aliquot all buffers in advance to ensure consistency

  • Include positive control samples in each experiment

  • Consider preparing a reference standard that can be included in all experiments

• Detection of multiple bands:

  • Verify if additional bands represent post-translational modifications

  • Increase gel resolution for better separation of closely migrating proteins

  • Use gradient gels for optimal separation of proteins with different molecular weights

  • Consider using more specific lysis conditions to minimize protein degradation

• Species cross-reactivity issues:

  • Verify antibody species reactivity claims with manufacturer

  • Compare sequences of the immunogen with the target species' SELENOW

  • Consider using species-specific antibodies when available

  • Validate cross-reactivity experimentally using positive controls from each species

How can SELENOW antibodies be effectively employed in studies of oxidative stress and redox signaling?

SELENOW functions as a glutathione (GSH)-dependent antioxidant, making it an excellent candidate for studying oxidative stress responses . When designing experiments to investigate these pathways:

• Oxidative challenge experimental design:

  • Compare SELENOW levels before and after oxidative stress induction (H₂O₂, paraquat, or menadione)

  • Use time-course experiments to track dynamic changes in SELENOW expression

  • Correlate SELENOW levels with established oxidative stress markers (8-oxo-dG, protein carbonylation)

  • Consider using redox-sensitive GFP fusion constructs alongside antibody detection

• Co-localization with redox partners:

  • Use dual immunofluorescence to examine SELENOW co-localization with glutathione reductase, thioredoxin, or peroxiredoxins

  • Apply proximity ligation assays to confirm direct protein-protein interactions

  • Consider FRET-based approaches for measuring dynamic interactions in living cells

• Redox state analysis:

  • Apply redox proteomics approaches to determine the oxidation state of SELENOW's cysteine residues

  • Use differential alkylation methods to trap different redox states

  • Compare wild-type SELENOW with cysteine mutants to determine functional importance

• Transcriptional regulation analysis:

  • Examine how oxidative stress affects SELENOW gene expression

  • Investigate potential antioxidant response elements in the SELENOW promoter

  • Consider CHIP-seq approaches to identify transcription factors regulating SELENOW expression

What role does SELENOW play in brain function and how can researchers best study these effects?

Recent research has revealed SELENOW's importance in brain function, particularly in fear memory formation, with notable gender-specific effects . When investigating SELENOW in neurological contexts:

• Behavioral assays in SELENOW knockout models:

  • Implement gender-balanced experimental designs due to observed sexual dimorphism in phenotypes

  • Apply a battery of behavioral tests assessing multiple cognitive domains

  • Include longitudinal assessments to determine age-dependent effects

  • Consider environmental enrichment protocols to assess plasticity

• Cellular mechanisms investigation:

  • Examine SELENOW's role in oligodendrogenesis using markers like MBP (Myelin Basic Protein)

  • Investigate neuron-glia interactions through co-culture systems

  • Apply electrophysiological approaches to assess functional outcomes

  • Consider single-cell RNA-seq to identify cell type-specific effects

• Proteomics approaches:

  • TMT-based quantitative proteomics of brain regions (hippocampus, amygdala) can reveal affected pathways

  • Compare proteome changes in wild-type and knockout animals before and after behavioral training

  • Validate key protein changes with Western blotting

  • Apply network analysis to identify functional protein clusters

• Experimental design considerations:

  • Include adequate biological replicates (n≥6 per group) due to inherent variability in brain tissue

  • Control for estrous cycle in female subjects

  • Consider using conditional knockouts to separate developmental from acute effects

  • Apply stimulus-response paradigms (e.g., fear conditioning) to evaluate dynamic processes

How can researchers optimize immunoprecipitation protocols for studying SELENOW interactors?

Identifying SELENOW's protein interaction partners is crucial for understanding its functional roles. An optimized immunoprecipitation (IP) protocol should include:

• Cell lysis optimization:

  • Use mild, non-denaturing lysis buffers to preserve protein-protein interactions

  • Include protease and phosphatase inhibitors to prevent degradation

  • Consider membrane-compatible detergents if studying membrane-associated interactions

  • Optimize buffer conditions (salt concentration, pH) based on predicted interaction strength

• IP procedure refinements:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Use sufficient amounts of SELENOW antibody (typically 2-5 μg per mg of total protein)

  • Include appropriate negative controls (non-specific IgG, lysates from SELENOW knockout cells)

  • Consider crosslinking approaches for transient interactions

• Validation approaches:

  • Confirm successful IP by Western blotting for SELENOW in input, unbound, and eluted fractions

  • Perform reverse IP experiments with antibodies against suspected interacting partners

  • Include stringent washing steps to remove non-specific binders

  • Consider using tagged SELENOW constructs as complementary approaches

• Analysis of interactors:

  • Apply mass spectrometry for unbiased identification of co-immunoprecipitated proteins

  • Use quantitative approaches (SILAC, TMT) to distinguish genuine interactors from background

  • Validate key interactions using orthogonal methods (proximity ligation assay, FRET)

  • Map interaction domains through truncation or point mutation experiments

What are the recommended positive and negative controls when working with SELENOW antibodies?

Implementing appropriate controls is essential for interpreting results with confidence:

Positive controls:

• Recombinant SELENOW protein - Useful for antibody validation and as a positive control in Western blots

• Cell lines with known high SELENOW expression - HepG2 liver cells or neuronal cells often express detectable levels

• Tissues from wild-type animals - Compare with matching tissues from knockout animals

• Overexpression systems - Cells transfected with SELENOW expression constructs

Negative controls:

• SELENOW knockout tissues or cells - The most stringent negative control

• siRNA/shRNA knockdown samples - Alternative when knockout models are unavailable

• Tissues known to have minimal SELENOW expression - Based on published expression atlases

• Primary antibody omission - Controls for non-specific binding of secondary antibodies

• Isotype control antibodies - Controls for non-specific binding of primary antibodies

Procedural controls:

• Loading controls for Western blots (GAPDH, β-Actin, β-Tubulin)

• Peptide competition controls - Pre-incubation with immunizing peptide should abolish specific signal

• Multiple antibody validation - Using antibodies targeting different epitopes of SELENOW

How can researchers interpret complex or conflicting SELENOW expression data across different experimental systems?

Researchers often encounter variations in SELENOW expression results across different systems or methodologies. A systematic approach to interpreting such data includes:

• Methodological considerations:

  • Different antibodies may recognize distinct epitopes or isoforms of SELENOW

  • Various detection methods have different sensitivity thresholds

  • Sample preparation can affect protein extraction efficiency

  • Consider whether post-translational modifications might affect antibody recognition

• Biological considerations:

  • SELENOW expression varies naturally across tissues and cell types

  • Gender-specific differences have been documented

  • Developmental stage affects expression patterns

  • Stress conditions or selenium status can dynamically regulate SELENOW levels

• Quantitative approach:

  • Normalize data appropriately for each technique

  • Consider absolute quantification methods for cross-platform comparisons

  • Apply statistical methods that account for technical and biological variability

  • Meta-analysis approaches can help integrate conflicting results

• Resolution strategies:

  • Employ orthogonal detection methods (e.g., mass spectrometry validation of antibody results)

  • Use genetic models (knockout/knockdown) to establish baseline

  • Consider the biological context when interpreting results

  • Design experiments that directly compare conditions using identical methodology

What are the best practices for studying SELENOW in primary cell cultures versus tissue samples?

Studying SELENOW across different experimental systems requires tailored approaches:

Primary Cell Cultures:

Tissue Samples:

• Sample preparation:

  • Optimize fixation protocols to preserve epitope accessibility

  • Consider regional heterogeneity within organs

  • Use consistent sampling locations across specimens

  • Flash-freezing is preferable for biochemical analyses

• Analytical approaches:

  • Immunohistochemistry provides spatial information within tissue architecture

  • Laser capture microdissection enables region-specific analysis

  • Western blotting requires careful homogenization and extraction

  • Consider multiplex immunofluorescence for co-localization studies

• Comparative strategies:

  • Use tissue microarrays for high-throughput comparisons

  • Include developmental time points to capture age-related changes

  • Compare matched tissues from multiple species for evolutionary insights

How can SELENOW antibodies contribute to understanding selenium deficiency pathophysiology?

SELENOW may play a role in the myopathies associated with selenium deficiency . To investigate this relationship:

• Experimental models:

  • Compare SELENOW expression in selenium-adequate versus deficient conditions

  • Examine tissue-specific changes, particularly in muscle and brain

  • Consider rescue experiments with selenium supplementation

  • Compare wild-type and SELENOW knockout responses to selenium deficiency

• Mechanistic investigations:

  • Examine SELENOW's relationship with other selenoproteins in deficiency states

  • Investigate compensatory mechanisms in chronic deficiency

  • Study SELENOW's role in protecting against oxidative damage during deficiency

  • Explore the regulation of SELENOW expression by selenium availability

• Clinical correlations:

  • Examine SELENOW levels in biobanked samples from selenium-deficient populations

  • Correlate SELENOW expression with clinical markers of deficiency

  • Consider genetic variations that might affect SELENOW function or expression

  • Examine SELENOW as a potential biomarker for selenium status

• Methodological approach:

  • Use carefully validated antibodies due to potential changes in epitope accessibility

  • Consider the impact of post-translational modifications in deficiency states

  • Apply systems biology approaches to place SELENOW in the context of broader selenium metabolism

What is the current understanding of SELENOW's role in inflammatory regulation and how can it be further investigated?

Recent research has identified SELENOW's importance in resolving inflammation, particularly in experimental colitis models . To advance this field:

• Inflammatory model systems:

  • Compare wild-type and SELENOW knockout responses in diverse inflammatory models (colitis, arthritis, etc.)

  • Examine tissue-specific inflammation resolution kinetics

  • Consider cell type-specific contributions using conditional knockouts

  • Investigate acute versus chronic inflammatory responses

• Mechanism exploration:

  • Further characterize the SELENOW-EGFR regulatory axis

  • Examine impacts on inflammatory cytokine production and signaling

  • Investigate effects on inflammatory cell recruitment and activation

  • Study effects on epithelial barrier function and repair mechanisms

• Therapeutic implications:

  • Explore SELENOW as a potential biomarker for inflammatory disease activity

  • Consider therapeutic approaches to modulate SELENOW function

  • Investigate interactions with current anti-inflammatory medications

  • Examine SELENOW in the context of precision medicine approaches

• Experimental design considerations:

  • Include time-course analyses to capture the dynamics of inflammatory resolution

  • Apply multi-omics approaches (transcriptomics, proteomics, metabolomics)

  • Consider sex as a biological variable due to documented gender-specific effects

  • Use tissue-specific conditional knockout models to dissect cell-autonomous effects

By implementing these methodologically rigorous approaches, researchers can continue to expand our understanding of SELENOW's diverse biological functions and potential therapeutic applications.